The Claim
In patients with acute coronary syndrome on statin therapy, high-dose eicosapentaenoic acid (EPA) at 1,800 mg/day or higher, regardless of docosahexaenoic acid (DHA) content, is associated with a 72% lower rate of coronary plaque progression over 1–2 years compared to no omega-3 supplementation, as measured by serial coronary computed tomography angiography.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with heart disease who are already taking statins, taking a high dose of a specific fish oil component called EPA (at least 1,800 mg a day) may slow down the buildup of plaque in their heart arteries by about 72% over a year or two, compared to not taking any fish oil at all.
See the scientific wording
In patients with acute coronary syndrome on statin therapy, high-dose eicosapentaenoic acid (EPA) at 1,800 mg/day or higher, regardless of docosahexaenoic acid (DHA) content, is associated with a 72% lower rate of coronary plaque progression over 1–2 years compared to no omega-3 supplementation, as measured by serial coronary computed tomography angiography.
What the research says
1 studyThis study found that people with heart problems who took a high dose of EPA (a type of fish oil) while already on statins had much less buildup of dangerous plaque in their heart arteries compared to those who didn’t take any fish oil. So yes, high-dose EPA helps slow heart artery clogging.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.